Download view brochure

HELP US TO MAKE A DIFFERENCE
We remain focused on addressing the world’s unmet healthcare needs, investing
in research and manufacturing, leaning on the legacy of our past and positioning
ourselves to provide the treatments which can contribute to wellbeing.
And we continue to explore and develop innovative ways of bringing our medicines
and services to the patient.
We all aspire to a world that is healthy – for ourselves, our families, our communities…
for now and for generations to come.
Let’s make a difference together.
For more information, drop us a line or call us – details below
CONTACT US
HEAD OFFICE
Merck Sharp & Dohme Limited
Hertford Road
Hoddesdon
Hertfordshire
EN11 9BU
T: 01992 467272
E: [email protected]
W:www.msd-uk.com
Merck Sharp & Dohme Limited. Registered Office: Hertford Road, Hoddesdon, Hertfordshire EN11 9BU.
Registered in England No. 820771.
© Merck Sharp & Dohme Limited 2016. All Rights Reserved.
CORP-1135892-0001
Date of preparation: November 2016
We are MSD – transforming
healthcare through innovative solutions
OUR
LOCATIONS...
1
NORTHUMBERLAND
FIRST AND FOREMOST –
A WORLD THAT IS WELL
Tablet manufacturing,
packaging and worldwide
supply. Global centre
for product safety and
efficacy testing.
For well over a century, MSD has been driven by a desire to preserve and improve health
all around the world. We produced the first tuberculosis vaccine and have continued
HERTFORDSHIRE
UK headquarters.
to bring a number of pioneering medicines in areas such as cardiovascular disease and
cancer treatment.
We are also investing in research and new treatments in areas of pressing patient need
such as dementia and antimicrobial resistance.
LONDON
We strive to make a difference in everything that we do:
•
Achieving scientific excellence
•
Operating with the highest standards of integrity
•
Expanding access to our products and services
Business Development
and Licencing hub for
Europe, the Middle East
and Africa.
BUCKINGHAMSHIRE
•
Employing a diverse workforce that values collaboration
“We try never to forget that medicine is for the people.
It is not for the profits… We cannot rest until the
way has been found with our help to bring our finest
achievements to everyone.” George W. Merck, 1950
Animal Health headquarters,
housing the largest
veterinary production facility
in the UK, commercial
operations and research
and development facilities.
WE ARE...
PASSIONATELY
COMMITTED TO
RESEARCH AND
INCREASING
ACCESS TO
HEALTHCARE
BRINGING THE
WORLD INNOVATIVE
MEDICINES AND
ANIMAL HEALTH
PRODUCTS
2
JUST AS OUR MEDICINES MATTER TO
PATIENTS WORLDWIDE, EACH OF OUR
EMPLOYEES MATTERS TO OUR COMPANY
Our employees are at the heart of everything that we do. We believe in supporting them
to deliver on promises to positively impact patients’ lives. With over 2000 committed
individuals working across a number of departments, we’re able to provide products and
services in key therapeutic areas such as: cardiovascular disease, oncology, infectious
diseases, women’s health, diabetes, immunology and anaesthetics. We are also the
OPERATING IN
140 COUNTRIES
UK’s number one provider of animal health products, supporting sustainable quality food
supplies, protecting public health and helping people and pets enjoy their lives together.
A variety of programmes ensures that our people can progress their skills and knowledge
and feel a strong sense of purpose and belonging. To work for MSD is to be part of
one big team with one common goal: helping to achieve well-being around the world.
THE LARGEST
PROVIDER OF
ANIMAL HEALTH
PRODUCTS IN THE
UNITED KINGDOM
We are called MSD
everywhere, except in the
United States and Canada,
where we are known as
Merck & Co., Inc.,
Kenilworth, NJ, USA.
3
4
MAKING GREAT STRIDES BY
COMBINING EFFORTS
We’re bold enough to want to change the world, but we’re smart enough to
know we can’t do it alone. No single provider has everything it takes to deliver
INNOVATING BEYOND THE PILL
While we continue to focus on our robust product pipeline, guided by the
healthcare needs of the population, we view innovation as vital in enabling us
to transform healthcare and improve the patient experience. We recognise the
value in finding innovative solutions beyond the pill to support patient care plus
complete healthcare.
reduce hospitalisations and other costly implications of disease.
We truly believe patient-centred solutions can only be delivered by the
effective integration of healthcare providers through joint working.
With the NHS facing funding shortfalls, we view our range of innovative services
as beneficial for both patients and our country’s largest healthcare provider. The
Currently, we’re working with the National Health Service (NHS) and we
Closercare patient-monitoring service allows patients with long-term conditions,
innovative treatments have a crucial role to play
such as heart failure and chronic obstructive pulmonary disease (COPD), to have
recognise that
in helping the NHS work more efficiently - whether that’s diabetes medicines
controlling blood sugar levels and reducing hospital stays; or life-saving cancer
treatments leading to
healthier lives.
their health monitored remotely while in the comfort of their own home.
50% drop in admissions from Closercare provided to patients
in Harrow with heart failure and COPD.
Our partnerships have also extended to work with universities and research
bodies, as well as commercial and non-profit organisations.
We’ve done great things for over 100 years.
Together, we’re doing great things for the future.
Innovative services support patients
and alleviate pressures on the NHS.
5
6
SCIENTIFIC DISCOVERIES LEADING THE WAY TO
MEDICAL TREATMENTS
Our research and development (R&D) might have begun in the UK over half a century ago, but our
global R&D story has been going even longer.
Over
150 years of tireless innovation worldwide and over £40 million spent annually
on research partnerships with NHS and academic centres.
People count on us to make medicines and vaccines that have well documented safety and
effectiveness profiles and which offer value. Clinical trials - also known as clinical studies - are a
critical step in this process.
100 clinical trials in the UK.
around 5,000 people are participating in these trials
At any one time, we are conducting approximately
On average,
each year.
7
8
MANUFACTURING: PRACTICAL VISIONARIES
Since 1975, our facility in Cramlington, Northumberland has been our manufacturing hub, producing
tablets for worldwide markets and finished packs for patients in the UK and other European markets.
Winners of the Best Factory Award for People and Skills Development in 2015, the team nurtures
talent and technological expertise both in the UK and in our manufacturing plants around the world
through close partnerships with universities.
We use leading-edge manufacturing technologies, high-volume packaging lines, a fully automated
warehouse; and paperless manufacturing operations. We are also the European centre for stability
testing, ensuring our products are safe and effective throughout their shelf life.
In the UK
we produce over 4 billion tablets a year.
10
GETTING TO THE HEART OF THE MATTER
Our commitment to cardiovascular care began with one of the first oral antihypertensive
medications in the 1950s and continued with research leading to new cholesterol-lowering
statins in the 1970s.
Our contribution has been significant in the fight against heart disease, the main cause of
premature death in the UK.
Cardiovascular disease (CVD) causes more than a quarter of all deaths in the UK, or around
160,000 deaths each year.
An estimated
7 million people are living with CVD in the UK, of which 2.3 million
people are living with coronary heart disease.
Today, we strive to meet even greater expectations by offering options for patients and healthcare
providers. These include treatments and tools for healthcare professionals to highlight where
treatment targets are not being met and suggesting where care can be improved.
We collaborate with professional and patient groups
to help prevent premature deaths caused by high
cholesterol and cardiovascular disease.
11
SUPPORT FOR THE MANAGEMENT OF CHRONIC
HEALTH CONDITIONS
There are
3.2 million people who have been diagnosed with diabetes in the UK, 10% of which
have Type 1 diabetes and 90% Type 2 diabetes.
It’s estimated that over 630,000 more people have the disease but have not been diagnosed.
By 2025 it is estimated that
5 million people will have diabetes, most of which will be Type 2
cases.
The implications of diabetes are considerable. Associated conditions including heart disease, stroke,
blindness and disability represent huge costs to patients and to the healthcare system.
Tackling diabetes requires a holistic approach that addresses lifestyle and helps people better
manage their condition.
MSD is committed to developing innovative
medicines to help people with diabetes
MSD and Schering-Plough merge to
create a stronger, more diverse global
healthcare company. The merger provides
sustainable growth with a more robust
pipeline, broader product portfolio and an
expanded global presence.
Ernst Schering, centre, with the
board of directors of Schering
AG circa 1885. The company was
incorporated in 1871.
The MSD Manual
begins publication,
providing professionals
with the best available
medical knowledge of
the day.
MSD’s penicillin “G”
(Penalev) is used in the
first successful
treatment of blood
infection with penicillin
in the U.S. Ramping up
production for the war
earns the company
the Army-Navy “E”
Award for excellence in
manufacturing.
The merger with
Sharp & Dohme
brings to the company
important new
expertise in
biologicals and
vaccine research,
and global
distribution.
1851 1885 1891 1899 1933 1942 1944 1953 1955
Dr. Ernst Christian
Friedrich Schering
begins developing
and selling
pharmaceutical
products in Berlin.
Three years later,
the company opens
its first production
facility.
In collaboration with
MSD, Dr. Selman
Waksman of Rutgers
University produces
streptomycin, the
world’s first cure
for tuberculosis. the
company waives the
patent rights.
Leaving Darmstadt,
Germany, George Merck
arrives in New York and
establishes Merck &
Co., Inc.
The founder’s son, George W.
Merck, launches major new
research laboratories in Rahway,
New Jersey, soon leading to
breakthroughs in vitamins,
antibiotics, and anesthetics.
Dr. E.B. Hershberg, standing
top right, leads the team
that synthesizes prednisone
and prednisolone. These
“Meti” drugs fuel Schering’s
second big wave of growth
in the mid-1950s.
A company foundation is
created to manage the
corporation’s growing
philanthropic endeavors.
In 1971 M-M-R II
(measles, mumps, and
rubella virus vaccine,
live) is launched in an
innovative combined
form.
Recombivax HB (hepatitis
B vaccine, recombinant)
is launched – the first
genetically engineered
vaccine approved for
humans, and the first to
prevent cancer.
Following a decade
of intensive research,
Crixivan (indinavir
sulfate) is approved
for treating HIV in just
45 days – one of the
fastest FDA reviews
to date.
In 2006 Gardasil
[Human Papillomavirus
Quadrivalent (Types 6,
11, 16, and 18) Vaccine,
Recombinant] becomes
the first vaccine to
prevent cervical cancer
(the second-leading
cause of cancer
deaths among women
worldwide).
Biopharmaceutical, Cubist is
purchased by MSD, further
strengthening the company’s
presence in Hospital Acute
Care, with a focus on
antibiotics, anti-infectives and
therapies to treat serious and
potentially life-threatening
infections.
MSD are joint winners of the
2012 UK Prix Galien Innovative
Product Award. The awards
aim to promote significant
advances in pharmaceutical
research. It also provides the
opportunity to give credit to
the most important medicines
introduced into the public
market.
1957 1958 1971 1985 1986 1987 1996 2005 2006 2009 2011 2012 2015
Diuril (chlorothiazide)
is launched for
congestive heart
failure and high blood
pressure – the first
major product in
the company’s new
cardiovascular line.
Considered the
most complex drug
synthesis process of
the time, the broadspectrum antibiotic
Primaxin is launched.
Mectizan (ivermectin)
is developed for river
blindness and distributed
free to all who need it.
Since then, the company
has donated 2.5 million
tablets (estimated value
of $3.75 billion).
CEO and President Dick Clark
launches the ”Plan to Win” to
address challenges and
transform the company into a
leader in the pharmaceutical
industry.
The company launches the
10-year MSD for Mothers
initiative, a global effort to
bring the issue of maternal
mortality to the forefront of
global consciousness.
Kenneth C. Frazier, the company’s
chairman, president and chief
executive officer, leads the
company into a new era of global
healthcare.
Early Access to Medicines
Scheme: MSD’s innovative
treatment for advanced
melanoma was the first drug
to be made available through
the government’s Early Access
to Medicines Scheme (EAMS)
- helping patients benefit
from promising, innovative
treatments in advance of
a European licence being
granted.
The Mectizan
Donation Program
celebrates its 25th
anniversary.
15
16
A COMMITMENT TO ONE OF OUR BIGGEST
HEALTH CHALLENGES
REFLECTING ON A DISTINGUISHED
HISTORY, LOOKING FORWARD TO
THE NEXT CENTURY OF DELIVERING
HEALTHCARE SOLUTIONS
Cancer is one of the most significant global health challenges today, representing one of the most
urgent unmet medical needs.
At MSD, our goal is to translate breakthrough science into biomedical innovations to help people with
cancer. For our oncology team, helping people fight cancer is our passion, supporting accessibility to
our cancer medicines is our commitment, and pursuing research in immuno-oncology is our focus
to potentially bring new hope to people with cancer.
first drug to gain approval
through the government’s innovative early access to medicines scheme
(EAMS), helping those patients, who have limited options, gain early access to medicines that
In 2015 MSD’s treatment for advanced melanoma was the
do not yet have a licence where there is a clear, unmet medical need.
17
PROVIDING CONTRACEPTIVE CHOICES
Around 50% of UK pregnancies, which end in childbirth, are unplanned.
Both unplanned pregnancies and terminations can place a physical and psychological impact upon
women who find themselves in this situation.
Through our portfolio of options and support for patients and healthcare professionals, we seek
to play a key role in raising awareness of contraceptive choices available to women to reduce
unplanned pregnancy.
This includes the development and maintenance of the online Talk Choice website, which provides
contraceptive advice. It aims to inform and educate women about the full range of contraceptive
options available to them, so they’re able to choose a suitable method that works with their body
and lifestyle.
www.talkchoice.co.uk
MSD’s Women’s Health Mission: to ensure that
every woman in the UK has awareness of, and easy
access to, the right contraceptive choice for her.
19
20
INNOVATIVE SOLUTIONS FOR SURGERY
FIGHTING INFECTION
MSD has been investing in anaesthesia since 1968 and more recently introduced
The rise in infections that are resistant to antibiotics has become one of the
the biggest advance in this area for 30 years – reshaping anaesthesia and
world’s most pressing public health problems.
highlighting our commitment to providing the best for patients.
With the acquisition of Cubist Pharmaceuticals, Inc., MSD has reaffirmed its
Muscle relaxation is vital to ensure that a patient remains still during surgery
commitment to develop new therapeutics to fight infectious diseases, building
to provide the surgeon with the best possible operating conditions. Just as
on both companies’ work in this area.
important is the reversal of this paralysis at the end of surgery, allowing a
patient’s recovery from anaesthesia at the planned time.
Antimicrobial research remains an important area of focus, in addition to
a combined portfolio of antibiotic and antifungal medicines, vaccines and
treatments for HIV and Hepatitis C.
We have been at the forefront of the global response to the HIV/AIDs epidemic
for around 30 years. Our scientists were among the first to discover and develop
medicines for HIV. Today, we continue with our commitment to address the
impact of this disease on patients, their families and carers.
Our therapies for infectious diseases also include medicines for the treatment
of Hepatitis C – affecting around 214,000 individuals in the UK, with many
unaware and undiagnosed until chronic symptoms arise.
There are over 2.8 million general anaesthetics given to
patients in the UK per year and 1.5 million of these are given
a muscle relaxant to paralyse them.
MSD has a long history of collaborating with other companies
in infectious diseases and the company was the first to
mass-produce penicillin for the war effort in the 1940s.
21
22
IMMUNITY BOOST
The last decade has brought major advances in the management of crippling autoimmune disease
such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and inflammatory bowel
disease.
Thanks to the advent of biologic therapies in the late 1980s, the control of immunological disease,
through suppression of inflammation, has helped improve patients’ lives.
MSD has biologic products in three therapeutic areas: gastroenterology, rheumatology and
dermatology. But we also know that successful disease management goes beyond medicines.
We invest extensively in hospital and educational programmes as well as options for people having
treatment at home.
We are fully dedicated to supporting the immunology
community, including collaborating with patient groups
on educational programmes to make a difference to
patients’ lives.
23
MSD FOR MOTHERS
OUR APPROACH TO
CORPORATE RESPONSIBILITY
Every two minutes, a woman somewhere in the world dies
Corporate responsibility at MSD is a commitment to discovering
due to complications from pregnancy or childbirth.
innovative solutions to the world’s greatest health challenges while
If nothing is done, an estimated 3 million women may
growing our business in a sustainable way. Each employee in the
die over the next 10 years. MSD for Mothers
UK is entitled to 40 volunteering hours each year to give back to
is a 10-year, US$500 million initiative
a recognised cause. Some of our projects include Dementia Friends,
focused on creating a world where no
Rennie Grove Hospice, the Scouts and Fareshare Foodbank.
woman has to die from complications
of pregnancy or childbirth
Focused on one thing:
saving women’s lives
RECOGNISING THE WORLD
AROUND US
Mectizan (ivermectin)
Donation Programme has donated
Since 1987, the
medicine and worked with a network of global
OUR APPROACH TO
CORPORATE RESPONSIBILITY
24
FOCUSES ON 4 KEY AREAS:
ACCESS TO HEALTH
We are committed to discovering smart sustainable
ways to expand global access to healthcare.
partners to eliminate river blindness. As a
result, the countries of Colombia and
Ecuador have received verification
from the World Health
Organisation (WHO) that this
goal has been achieved. As of
ENVIRONMENTAL SUSTAINABILITY
We are committed to discovering environmentally
sustainable ways to meet the world’s health needs,
now and in the future.
2015, Mexico and Guatemala
have both finished their
post-treatment surveillance
period and are waiting for
the verification process from
the WHO. Eight countries in
Africa are hoping to complete
EMPLOYEES
We are committed to discovering more ways to
create a workplace where our employees and
business can thrive.
final tests for stopping treatment
by 2016.
We are also working with the World
Health Organisation and other partners to
control or eliminate 10 of the 17 neglected tropical
diseases by 2020.
ETHICS & TRANSPARENCY
We are committed to discovering better ways
to build and strengthen trusted relationships
by demonstrating the highest ethical standards
and communicating with greater transparency.
25
MAN’S BEST FRIEND AND MORE
Animal Health is the UK’s largest provider of animal health products, and the second largest in the
world; with products in more than 140 countries.
Feathers, fur or fins – MSD Animal Health offers the widest range of veterinary pharmaceuticals,
vaccines and health management solutions and services.
As the people behind THE SCIENCE OF HEALTHIER ANIMALS, we understand the science of
running a business, the science of food safety and supply and the science of keeping people happy
by protecting and caring for their pets.
We are dedicated to preserving and improving the health, well-being and performance of animals.
That’s what makes us the leading animal health company in the UK.
MSD Animal Health – THE SCIENCE OF HEALTHIER ANIMALS.
For further details, visit the Animal Health website:
provider
of animal
health
products
in the UK
www.msd-animal-health.co.uk
Products
in more
than
140
countries